Evidence map›Paper›PMID 30539383›Full record

ReviewJournal of medical toxicology : official journal of the American College of Medical Toxicology2019

A Review on Ingested Cyanide: Risks, Clinical Presentation, Diagnostics, and Treatment Challenges.

Tara B Hendry-Hofer, Patrick C Ng, Alyssa E Witeof, Sari B Mahon, Matthew Brenner, Gerry R Boss, Vikhyat S Bebarta

Abstract readReview
In one paragraph

Review in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A clinical review of acute poisoning among pediatric individuals.European journal of medical research · 2025
    Article
  9. Article
  10. Article
  11. Intranasal Dimethyl Trisulfide: Long-Term Efficacy in an Acutely Lethal Large Swine Model of Cyanide Exposure.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2025
    Article
  12. Article
  13. Redirecting Intermediary Metabolism to Counteract Cyanide Poisoning.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tara B Hendry-HoferDepartment of Emergency Medicine and Toxicology, University of Colorado School of Medicine, 12700 E. 19th Ave., Aurora, CO, 80045, USA. Tara.hendry-hofer@ucdenver.edu.ORCID http://orcid.org/0000-0002-0576-753X
Patrick C NgDepartment of Emergency Medicine and Toxicology, University of Colorado School of Medicine, 12700 E. 19th Ave., Aurora, CO, 80045, USA.
Alyssa E WiteofDepartment of Emergency Medicine and Toxicology, University of Colorado School of Medicine, 12700 E. 19th Ave., Aurora, CO, 80045, USA.
Sari B MahonBeckman Laser Institute, University of California, Irvine, CA, USA.
Matthew BrennerBeckman Laser Institute, University of California, Irvine, CA, USA.
Gerry R BossDepartment of Medicine, University of California, San Diego, CA, USA.
Vikhyat S BebartaDepartment of Emergency Medicine and Toxicology, University of Colorado School of Medicine, 12700 E. 19th Ave., Aurora, CO, 80045, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyanide, a metabolic poison, is a rising chemial threat and ingestion is the most common route of exposure. Terrorist organizations have threatened to attack the USA and international food and water supplies. The toxicokinetics and toxicodynamics of oral cyanide are unique, resulting in high-dose exposures, severe symptoms, and slower onset of symptoms. There are no FDA-approved therapies tested for oral cyanide ingestions and no approved intramuscular or oral therapies, which would be valuable in mass casualty settings. The aim of this review is to evaluate the risks of oral cyanide and its unique toxicokinetics, as well as address the lack of available rapid diagnostics and treatments for mass casualty events. We will also review current strategies for developing new therapies. A review of the literature using the PRISMA checklist detected 7284 articles, screened 1091, and included 59 articles or other reports. Articles referenced in this review were specific to risk, clinical presentation, diagnostics, current treatments, and developing therapies. Current diagnostics of cyanide exposure can take hours or days, which can delay treatment. Moreover, current therapies for cyanide poisoning are administered intravenously and are not specifically tested for oral exposures, which can result in higher cyanide doses and unique toxicodynamics. New therapies developed for oral cyanide exposures that are easily delivered, safe, and can be administered quickly by first responders in a mass casualty event are needed. Current research is aimed at identifying an antidote that is safe, effective, easy to administer, and has a rapid onset of action.

Indexed as

Administration, OralAntidotesCyanidesHumansMass Casualty IncidentsPoisoningRiskTerrorismToxicokineticsAntidotesCyanidesCyanideDiagnosisIngestionTreatment

Identifiers

PMID30539383
PMCPMC6441064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.